bad science, bad for humanity, and bad business - if trial populations are not diverse and adverse events happen outside the trial population post launch, it could end an approved drug. pharma companies that ignore human diversity do so at their peril
Reposted from
David Shaywitz
Especially shocking because diversity of clinical trials is squarely a scientific necessity if the results are to be representative of and generalizable to the broader population. It's bad science to test a candidate medicine in a non-representative population.
Comments